Key Insights

Highlights

Success Rate

86% trial completion

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 62/100

Termination Rate

8.2%

4 terminated out of 49 trials

Success Rate

85.7%

-0.8% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

8%

2 of 24 completed with results

Key Signals

2 with results86% success

Data Visualizations

Phase Distribution

41Total
Not Applicable (6)
P 1 (31)
P 2 (4)

Trial Status

Completed24
Recruiting9
Active Not Recruiting6
Unknown5
Terminated4
Not Yet Recruiting1

Trial Success Rate

85.7%

Benchmark: 86.5%

Based on 24 completed trials

Clinical Trials (49)

Showing 20 of 20 trials
NCT07209111Phase 2RecruitingPrimary

A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014)

NCT03911388Phase 1Recruiting

HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors

NCT04733469Not ApplicableActive Not Recruiting

EMPOWER 3: Improving Palliative Care Health Literacy and Utilization

NCT06782451Not ApplicableRecruitingPrimary

Development of Preclinical Models Derived From Tumors With a Molecular Abnormality of Interest to Test Their Sensitivity to New Anti-tumor Therapies.

NCT05013554Phase 1TerminatedPrimary

Dose Escalation and Expansion Study of SAR443216 in Participants With Relapsed/Refractory HER2 Expressing Solid Tumors

NCT03324113Phase 1CompletedPrimary

Evaluation of SAR408701 in Japanese Patients With Advanced Malignant Solid Tumors

NCT05818865Not ApplicableActive Not RecruitingPrimary

"Principle Test" for Isolation and Characterization of Circulating Cancer Cells (CTC)-CXCR4+.

NCT05714553Phase 1Terminated

NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours

NCT04987359Not ApplicableActive Not RecruitingPrimary

A Trial of a Multimodal Lifestyle Intervention to Optimize Survivorship After Cancer

NCT06606366Not ApplicableRecruitingPrimary

Study on the Contribution of the Genetic Tumor Profile Obtained by Circulating Tumor DNA Analysis in the Multidisciplinary Molecular Biology Meeting of Eastern PACA

NCT04976634Phase 2Active Not RecruitingPrimary

Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016)

NCT04401020Phase 1Active Not RecruitingPrimary

First-in-human Single Agent Study of SAR442257 in RRMM and RR-NHL

NCT01836705Phase 1CompletedPrimary

Effect of SAR302503 on ECG Activity in Patients With Solid Tumors

NCT02187848Phase 1TerminatedPrimary

Evaluation of SAR408701 in Patients With Advanced Solid Tumors

NCT03667716Phase 1Completed

COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.

NCT03845166Phase 1Active Not RecruitingPrimary

A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors

NCT06575127Phase 2RecruitingPrimary

Modified FOLFOXIRI Plus Target Therapy as a First Line Treatment for Advanced Colorectal Cancer a Prospective Phase Two Study

NCT04726332Phase 1TerminatedPrimary

Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101)

NCT06332001RecruitingPrimary

Evaluation of a Music and Interaction Intervention on Patient Distress During Whole Body Magnetic Resonance

NCT04200963Phase 1Completed

A Phase 1a/b Study of IK-175 as a Single Agent and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors and Urothelial Carcinoma

Scroll to load more

Research Network

Activity Timeline